Gan & Lee Pharmaceuticals Partners with JW Pharmaceutical to Advance Bofanglutide in South Korea's Metabolic Market
Gan & Lee Pharmaceuticals, a leading biopharmaceutical company based in China, has lit up the pharmaceutical landscape with its recent exclusive licensing agreement with JW Pharmaceutical, a top player in South Korea's health industry. The agreement focuses on the development and commercialization of Bofanglutide Injection, a pioneering bi-weekly GLP-1 receptor agonist developed by Gan & Lee. This innovative therapy targets key metabolic diseases, including obesity, type 2 diabetes, and obstructive sleep apnea.
Initially announced on April 9, 2026, the agreement grants JW Pharmaceutical exclusive rights in South Korea to proceed with clinical development and regulatory filings for this promising treatment. Gan & Lee stands to benefit significantly from this collaboration; they will receive an upfront payment of USD 5 million and are eligible for milestone payments that could sum up to USD 76.1 million, based on successful regulatory outcomes and other commercial achievements. Once the product hits the market, royalties based on net sales will further enhance the financial rewards of this strategic partnership. The total value of this agreement could soar to USD 81.1 million, highlighting Gan & Lee's strong positioning in the global pharma market.
This agreement is not Gan & Lee's first foray into international licensing, as it marks the third overseas licensing deal for Bofanglutide, following partnerships in Latin America and India. Bofanglutide sets itself apart as a bi-weekly administered GLP-1 receptor agonist, a feature that aims to significantly enhance patient compliance. Existing clinical data has shown that Bofanglutide effectively reduces body weight and improves blood glucose levels. Moreover, its bi-weekly regimen cuts down annual injection frequencies by 50% compared to common weekly treatments, aiming to revolutionize how patients manage their metabolic conditions.
The need for effective and accessible treatments for metabolic diseases is crucial, especially in South Korea, which is emerging as a key player in the pharmaceutical landscape. The demand for GLP-1 therapies is set to surge, with the Asia-Pacific market for these treatments expected to balloon from USD 5.47 billion in 2025 to an impressive USD 16.95 billion by 2033, reflecting a compound annual growth rate (CAGR) of 14%.
Dr. Zhi Li, Chief Business Officer at Gan & Lee, emphasized that this partnership with JW Pharmaceutical signifies a crucial milestone in their expandability not only in South Korea but also in the wider Asia-Pacific region. He underscored the commitment to meet the pressing medical needs within the market by leveraging JW’s established experience in the field of metabolic diseases. Young-sub Shin, CEO of JW Pharmaceutical, echoed this sentiment, stating that the partnership would enhance their portfolio and ensure innovative solutions are made available to South Korean patients facing challenges from metabolic diseases.
Bofanglutide is primed to become a game changer in therapy for metabolic disorders, with a focus on improving patient adherence through its unique dosage regimen. Its safety profile aligns well with established GLP-1 drugs, reinforcing its potential as a first commercially available bi-weekly GLP-1 receptor agonist. With the global burden of obesity and diabetes on the rise, this collaborative effort could provide critical support to the treatment landscape, addressing urgent unmet medical needs while also paving the way for Gan & Lee’s strategic global expansion.
In an industry where innovation is paramount, Gan & Lee’s dedication to developing cutting-edge treatments for metabolic diseases signals a bright future. Their collaboration with JW Pharmaceutical stands as a testament to the potential of international partnerships in driving forward advancements in medical science. Bofanglutide aims not only to deliver important clinical benefits but also to establish a strong commercial foundation in South Korea’s growing pharmaceutical market, marking a significant chapter in Gan & Lee Pharmaceuticals' journey toward global healthcare impact.
Initially announced on April 9, 2026, the agreement grants JW Pharmaceutical exclusive rights in South Korea to proceed with clinical development and regulatory filings for this promising treatment. Gan & Lee stands to benefit significantly from this collaboration; they will receive an upfront payment of USD 5 million and are eligible for milestone payments that could sum up to USD 76.1 million, based on successful regulatory outcomes and other commercial achievements. Once the product hits the market, royalties based on net sales will further enhance the financial rewards of this strategic partnership. The total value of this agreement could soar to USD 81.1 million, highlighting Gan & Lee's strong positioning in the global pharma market.
This agreement is not Gan & Lee's first foray into international licensing, as it marks the third overseas licensing deal for Bofanglutide, following partnerships in Latin America and India. Bofanglutide sets itself apart as a bi-weekly administered GLP-1 receptor agonist, a feature that aims to significantly enhance patient compliance. Existing clinical data has shown that Bofanglutide effectively reduces body weight and improves blood glucose levels. Moreover, its bi-weekly regimen cuts down annual injection frequencies by 50% compared to common weekly treatments, aiming to revolutionize how patients manage their metabolic conditions.
The need for effective and accessible treatments for metabolic diseases is crucial, especially in South Korea, which is emerging as a key player in the pharmaceutical landscape. The demand for GLP-1 therapies is set to surge, with the Asia-Pacific market for these treatments expected to balloon from USD 5.47 billion in 2025 to an impressive USD 16.95 billion by 2033, reflecting a compound annual growth rate (CAGR) of 14%.
Dr. Zhi Li, Chief Business Officer at Gan & Lee, emphasized that this partnership with JW Pharmaceutical signifies a crucial milestone in their expandability not only in South Korea but also in the wider Asia-Pacific region. He underscored the commitment to meet the pressing medical needs within the market by leveraging JW’s established experience in the field of metabolic diseases. Young-sub Shin, CEO of JW Pharmaceutical, echoed this sentiment, stating that the partnership would enhance their portfolio and ensure innovative solutions are made available to South Korean patients facing challenges from metabolic diseases.
Bofanglutide is primed to become a game changer in therapy for metabolic disorders, with a focus on improving patient adherence through its unique dosage regimen. Its safety profile aligns well with established GLP-1 drugs, reinforcing its potential as a first commercially available bi-weekly GLP-1 receptor agonist. With the global burden of obesity and diabetes on the rise, this collaborative effort could provide critical support to the treatment landscape, addressing urgent unmet medical needs while also paving the way for Gan & Lee’s strategic global expansion.
In an industry where innovation is paramount, Gan & Lee’s dedication to developing cutting-edge treatments for metabolic diseases signals a bright future. Their collaboration with JW Pharmaceutical stands as a testament to the potential of international partnerships in driving forward advancements in medical science. Bofanglutide aims not only to deliver important clinical benefits but also to establish a strong commercial foundation in South Korea’s growing pharmaceutical market, marking a significant chapter in Gan & Lee Pharmaceuticals' journey toward global healthcare impact.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.